Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Tagrisso Approved in China as 1st-Line Treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/04/2019 | 02:41am EDT

By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) said Wednesday that China's medicines watchdog has approved the use of its drug Tagrisso as a first-line treatment for nonsmall cell lung cancer.

The U.K. pharmaceutical company said the medicine has been approved for patients with locally-advanced or metastatic cancer, and with tumors that showed certain genetic mutations, based on positive results from the phase 3 Flaura trial.

In the trial, Tagrisso used as a primary therapy was able to increase the amount of time patients lived without dying, or without having the disease progress, by a median of 18.9 months, versus 10.2 months for those being administered a standard alternative treatment.

Tagrisso was first approved in China in 2017 as a second-line treatment. With this approval, it will be able to be administered sooner after a patient is diagnosed.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
09/19LONDON MARKETS: U.K. Stocks Snap Three-day Losing Run
DJ
09/18LONDON STOCK EXCHANGE : FTSE 100 lingers in red as Fed decision looms and Kingfi..
RE
09/18IRONWOOD PHARMACEUTICALS : AstraZeneca amends collaboration with Ironwood for Li..
AQ
09/18ASTRAZENECA : amends collaboration with Ironwood for Linzess in China
PU
09/18AstraZeneca Amends China Collaboration Agreement With Ironwood
DJ
09/18ASTRAZENECA : amends collaboration with Ironwood
PU
09/18ASTRAZENECA : amends collaboration with Ironwood for Linzess in China
AQ
09/17LONDON STOCK EXCHANGE : London's FTSE 100 ends on a flat note, Sirius Minerals p..
RE
09/16ASTRAZENECA : FDA Grants Fast Track Designation for Farxiga in Heart Failure
DJ
09/16ASTRAZENECA : redefines cancer treatment with practice-changing data at ESMO 201..
PU
More news
Financials (USD)
Sales 2019 23 963 M
EBIT 2019 6 402 M
Net income 2019 2 299 M
Debt 2019 11 472 M
Yield 2019 3,13%
P/E ratio 2019 50,1x
P/E ratio 2020 36,0x
EV / Sales2019 5,37x
EV / Sales2020 4,89x
Capitalization 117 B
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 93,80  $
Last Close Price 89,43  $
Spread / Highest target 45,0%
Spread / Average Target 4,89%
Spread / Lowest Target -29,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA22.03%116 691
JOHNSON & JOHNSON1.05%343 382
ROCHE HOLDING LTD.16.27%243 639
MERCK AND COMPANY9.89%214 995
PFIZER-16.36%201 939
NOVARTIS15.60%198 194